Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia, Schizoaffective Disorder
Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers
Negative symptoms significantly interfere with daily functioning among individuals with schizophrenia. They are strongly related to functional impairments [1] and contribute to the poor community outcomes of Veterans with…
- Trial name
- NCT02386605
- Testing
- Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- VA Office of Research and Development
Psychosis
NAPLS Omega-3 Fatty Acid Versus Placebo Study
The overall goal of the present study is to determine whether Omega-3 Fatty Acids potentially prevent onset of psychosis and improve clinical symptoms and functional outcome in youth and young adults at elevated clinical risk for…
- Trial name
- NCT01429454
- Testing
- Omega-3 Long Chain Fatty Acid
- Where
- 9 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- University of California, San Diego
Schizophrenia
The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia
The purpose of this study is to better understand the neural correlates of cognitive control (CC) deficits in schizophrenia and determine how these mechanisms can be modulated by transcranial direct current stimulation (tDCS).
- Trial name
- NCT03077347
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
This is an extension study to further test the efficacy and safety of asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of schizophrenia.
- Trial name
- NCT00265343
- Testing
- asenapine, olanzapine
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Chronic Schizophrenia
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term…
- Trial name
- PEARL 3 Ext (NCT00789698)
- Testing
- Lurasidone HC1, Quetiapine XR
- Where
- 65 sites in United States, Colombia and 4 more
- Volunteers
- 240 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
The purpose of this trial is to assess the effect of asenapine 2.5 and 5 mg sublingually twice daily (BID) compared with placebo in the treatment of schizophrenia (overall symptoms) as measured by the Positive and Negative…
- Trial name
- NCT01617187
- Testing
- Asenapine, Olanzapine
- Volunteers
- 360 people
- Sponsor
- Organon and Co
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia
Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
This will be a phase IV 20 -32 day prospective, double blind, double-dummy, randomised crossover study that will evaluate the effect of quetiapine XR and quetiapine IR on cognitive performance in patients with schizophrenia…
- Trial name
- eXtRa (NCT01213836)
- Testing
- Seroquel XR- quetiapine fumarate extended release, Seroquel IR - quetiapine fumarate
- Where
- 20 sites in Austria, Denmark and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Paranoia, Schizophrenia-spectrum Diagnosis
The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia
This study aims to evaluate a novel group psychological intervention targeting anxiety triggered by urban environments for people with paranoia.
- Trial name
- NCT02408198
- Testing
- Anxiety intervention
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- King's College London
Schizophrenia
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and…
- Trial name
- NCT02002832
- Testing
- Lurasidone tablets, Risperidone tablets
- Where
- 15 sites in China
- Volunteers
- 388 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia, Hallucinations
Transcranial Magnetic Stimulation for "Voices"
This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00308997
- Testing
- 1-hertz Repetitive Transcranial Magnetic Stimulation, Active 1-Hertz Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Yale University
Schizophrenia
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia
- Trial name
- ADVANCE-2 (NCT04531982)
- Testing
- Pimavanserin
- Where
- 102 sites in Argentina, Bulgaria and 10 more
- Volunteers
- 454 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Bipolar Disorder, Schizo Affective Disorder
Brain Stimulation and Cognitive Training
People with serious mental illness often report difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
- Trial name
- NCT03338673
- Testing
- tDCS, BrainHQ
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Schizophrenia
A Study of Cognitive Adaptation Training in Inpatient Forensic Environments
The proposed project will be a mixed-methods feasibility study of modified Cognitive Adaptation Training for an inpatient forensic mental health population (finCAT).
- Trial name
- finCAT (NCT04294719)
- Testing
- Cognitive Adaptation Training (CAT)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia
- Trial name
- NCT00088634
- Testing
- Lurasidone
- Where
- 22 sites in United States
- Volunteers
- 180 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been…
- Trial name
- NCT04115319
- Testing
- SEP363856, quetiapine XR
- Where
- 42 sites in United States, Romania and 2 more
- Volunteers
- 305 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophrenia-related Psychotic Disorder
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
A study to compare the change in symptom severity in participants with schizophrenia or related psychotic disorder when treated with GWP42003 or placebo in conjunction with existing anti-psychotic therapy over a period of six…
- Trial name
- NCT02006628
- Testing
- GWP42003
- Where
- 14 sites in Poland, Romania and 1 more
- Volunteers
- 88 people
- Sponsor
- Jazz Pharmaceuticals